PTC Therapeutics Posts $831M Product and Royalty Revenue, Completes $240M Evrysdi Royalty Sale
PTC Therapeutics reported 2025 product and royalty revenue of $831M, including $92M in Q4 and $111M from Sephience, ending the year with $1.95B cash. The company sold Evrysdi royalties for $240M upfront plus up to $60M in milestones, delivered $682.6M net income, plans Sephience launches in 20–30 countries by end-2026.
1. Full-Year 2025 Financial Performance
PTC Therapeutics reported total revenues of $164.7M in Q4 2025 and $1.731B for full year 2025, compared to $213.2M in Q4 2024 and $806.8M in full year 2024, driven by $998.4M collaboration revenue from the votoplam agreement. The company recorded $682.6M net income for 2025 versus a $363.3M loss in 2024 and held $1.945B in cash, cash equivalents, and marketable securities as of December 31.
2. Sephience Launch and Uptake
Sephience™ generated $92M in Q4 revenue ($81M US, $11M ex-US) and $111M in net revenue since its mid-2025 launch. As of year-end, 946 patients are on commercial therapy worldwide with 1,134 US patient start forms, approvals secured in Japan and Brazil, and a goal to expand to 20–30 countries by end-2026.
3. Evrysdi Royalty Sale
In December 2025, the company sold its remaining Evrysdi (risdiplam) royalty to Royalty Pharma for $240M upfront plus up to $60M in sales-based milestones. PTC retains a $150M milestone right from Roche upon Evrysdi reaching $2.5B in annual sales and recognized $244.2M in Evrysdi royalty revenue for 2025.
4. Pipeline and Future Outlook
PTC held an End-of-Phase 2 FDA meeting for its votoplam Huntington’s disease program, aligning on a global Phase 3 INVEST-HD trial slated for early 2026 and exploring an Accelerated Approval pathway. A Type C FDA meeting on vatiquinone for Friedreich’s ataxia indicated need for an additional open-label study with a natural history control for NDA resubmission.